TY - JOUR
T1 - Interferon γ and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment
AU - Franciotta, Diego
AU - Zardini, E.
AU - Bergamaschi, R.
AU - Andreoni, L.
AU - Cosi, V.
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Intracellular cytokine flow cytometry was used to analyse the percentages of interferon (IFN) γ and interleukin (IL)-4 producing T cells in the peripheral blood of multiple sclerosis patients, before and after immunomodulotory treatment, and of heolthy controls. After six months of treatment, different doses of IFN β1 o (Avonex or Rebif) decreased CD4+ (Th1, Th2) ond CD8+ (Tc1) cells to a similar extent, without affecting the Th1/Th2 ratio. These T cell subsets were unmodified after nine months: of glatiramer acetate (Capaxone) treatment, and after six day courses of high dose 6-methylprednisolone. The data suggest that IFN β1 a produces sustained downmodulation of IFN γ and IL-4 producing T cells in vivo, which may contribute to its therapeutic efficacy; that glatiramer acetate possibly acts without altering non-specific cellular immunity; and that glucocorticoid induced lymphocytopenia does not affect the percentages of Th1, Th2 and Tc1 cells; at least in the periphery, none of the treatments caused a Th1 to Th2 shift that could account for their respective therapeutic effects.
AB - Intracellular cytokine flow cytometry was used to analyse the percentages of interferon (IFN) γ and interleukin (IL)-4 producing T cells in the peripheral blood of multiple sclerosis patients, before and after immunomodulotory treatment, and of heolthy controls. After six months of treatment, different doses of IFN β1 o (Avonex or Rebif) decreased CD4+ (Th1, Th2) ond CD8+ (Tc1) cells to a similar extent, without affecting the Th1/Th2 ratio. These T cell subsets were unmodified after nine months: of glatiramer acetate (Capaxone) treatment, and after six day courses of high dose 6-methylprednisolone. The data suggest that IFN β1 a produces sustained downmodulation of IFN γ and IL-4 producing T cells in vivo, which may contribute to its therapeutic efficacy; that glatiramer acetate possibly acts without altering non-specific cellular immunity; and that glucocorticoid induced lymphocytopenia does not affect the percentages of Th1, Th2 and Tc1 cells; at least in the periphery, none of the treatments caused a Th1 to Th2 shift that could account for their respective therapeutic effects.
UR - http://www.scopus.com/inward/record.url?scp=0037228948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037228948&partnerID=8YFLogxK
U2 - 10.1136/jnnp.74.1.123
DO - 10.1136/jnnp.74.1.123
M3 - Article
C2 - 12486283
AN - SCOPUS:0037228948
VL - 74
SP - 123
EP - 126
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
SN - 0022-3050
IS - 1
ER -